Nicolas Dupré
Chercheur universitaire clinicien
Axe Neurosciences
Neurogénétique
Publications
View all-
article Labrèche F, Prud'homme P, Gagnon M, Dupré N, Gravel S
Occupational exposure to pesticides increases the risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis
Occup Environ Med 83 (5), 2026.
-
article Bouhadoun S, Taylor KI, Lambrecht S, Popp WL, Kwasny D, Lindemann M, McKeown MJ, Duquette A, Jodoin N, Soland V, Dupré N, Anang J, Connolly BS, Schoffer K, Grimes DA, Postuma RB
Smartphone-derived digital motor measures to monitor progression in idiopathic REM sleep behavior disorder
NPJ Parkinsons Dis 2026.
-
article Senkevich K, Parlar SC, Chantereault C, Liu L, Yu E, Rudakou U, Ahmad J, Ruskey JA, Asayesh F, Spiegelman D, Waters C, Monchi O, Dauvilliers Y, Dupré N, Greenbaum L, Hassin-Baer S, Miliukhina I, Timofeeva A, Emelyanov A, Pchelina S, Alcalay RN, Gan-Or Z
Rare-Variant Burden across Lysosomal Genes Implicates Sialylation and Ganglioside Metabolism in Parkinsons Disease
Mov Disord 2026.
Projects
- Depicting disease heterogeneity in neurofibromatosis type 1 and the role of dermal fibroblasts in the establishment of microenvironment favouring NF1-associated skin tumor formation using personalized tissue-engineered 3D models, from 2023-10-01 to 2028-09-30
- Étudier le rôle de la matrice extracellulaire dans la Sclérose Latérale Amyotrophique à l'aide de modèles in vitro 3D personnalisés produits par génie tissulaire, from 2025-10-01 to 2030-09-30
- Bridge Fund Request to ALS Québec to Ensure Continuity of Strategic Research Infrastructure, from 2026-01-01 to 2027-01-31
- Comprehensive Analysis Platform To Understand,Remedy and Eliminate ALS, from 2021-01-01 to 2026-06-30
- Digital measurement of gait as a potential pharmacodynamic/response biomarker for ALS-FTSD , from 2022-09-01 to 2025-06-30
- Développement d’un registre de patients sur la neurofibromatose , from 2023-08-03 to 2026-08-03
- Étude rétrospective sur le recours à l’aide médicale à mourir en sclérose latérale amyotrophique (SLA/AMM) au CHU de Québec-Université Laval., from 2023-10-24 to 2025-11-01
- L'hyperhomocystéinémie:étude de son potentiel comme biomarqueur du déclin cognitif commun à la démence à corps de Lewy et à la maladie de parkinson pour améliorer le diagnostic et le traitement des patients, from 2024-01-23 to 2026-03-31
- A transcriptomic approach to drug discovery against ARSACS, from 2025-08-01 to 2026-08-31
- Chemosensation in Parkinson's disease: Trigeminal sensitivity as a potential marker, from 2020-10-01 to 2025-09-30